Loading...
Please wait, while we are loading the content...
Similar Documents
Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?
| Content Provider | CiteSeerX |
|---|---|
| Abstract | A trial fibrillation (AF) is the most common cardiacarrhythmia, and those afflicted have reduced quality of life, functional status, and cardiac performance.1 Patients with AF have a higher risk of stroke, heart failure, and premature death relative to patients without AF.2 It is estimated that 2.5 % of the population worldwide has AF, and the prevalence of AF increases substantially with age, especially after 50 years of age.3 AF is more common among white persons than black persons, and men are at 1.5 times greater risk for developing AF than women.3,4 In the United States, about 2.3 million people currently have AF, and the numbers are increasing rapidly. It is predicted that by 2050, 5.6 million people in the United States will have AF, with more than half of those patients aged>80 years.3 This represents a 2.5-fold increase over 50 years, reflecting both the growing proportion of elderly persons in the population3 |
| File Format | |
| Access Restriction | Open |
| Content Type | Text |
